Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_3
1
20%
Ph phase_2
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting2
Terminated1
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

not_yet_recruiting240%
terminated120%
completed120%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
terminatedphase_3

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

NCT05338450
recruitingphase_1

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653
not_yet_recruitingphase_1

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06065670
not_yet_recruitingphase_2

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
completedphase_1

Effect of Clemastine Fumarate on Color Vision in Healthy Controls

NCT02613091

Clinical Trials (5)

Showing 5 of 5 trials
NCT05338450Phase 3

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

Terminated
NCT05359653Phase 1

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Recruiting
NCT06065670Phase 1

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Not Yet Recruiting
NCT06591091Phase 2

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

Not Yet Recruiting
NCT02613091Phase 1

Effect of Clemastine Fumarate on Color Vision in Healthy Controls

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5